BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 270 filers reported holding BIO-TECHNE CORP in Q1 2017. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $347 | -60.9% | 5,102 | -57.4% | 0.03% | -65.9% |
| Q1 2023 | $888 | -99.8% | 11,963 | +542.5% | 0.09% | +25.7% |
| Q3 2022 | $529,000 | +52.4% | 1,862 | +33.0% | 0.07% | +20.7% |
| Q3 2020 | $347,000 | -77.1% | 1,400 | -79.7% | 0.06% | -67.2% |
| Q4 2019 | $1,516,000 | +38.7% | 6,908 | +23.7% | 0.18% | +19.6% |
| Q3 2019 | $1,093,000 | -51.0% | 5,586 | -47.8% | 0.15% | -40.8% |
| Q2 2019 | $2,229,000 | -15.0% | 10,693 | -19.0% | 0.25% | -6.0% |
| Q1 2019 | $2,623,000 | +64.7% | 13,209 | +20.0% | 0.27% | +44.6% |
| Q4 2018 | $1,593,000 | -17.2% | 11,009 | +16.8% | 0.18% | +73.6% |
| Q3 2018 | $1,923,000 | +195.4% | 9,423 | +114.2% | 0.11% | +231.2% |
| Q2 2018 | $651,000 | -21.7% | 4,400 | -20.0% | 0.03% | -27.3% |
| Q1 2018 | $831,000 | +136.8% | 5,500 | +89.7% | 0.04% | +83.3% |
| Q3 2017 | $351,000 | -48.5% | 2,900 | -50.0% | 0.02% | -46.7% |
| Q2 2017 | $682,000 | -79.4% | 5,800 | -82.2% | 0.04% | -74.7% |
| Q1 2017 | $3,314,000 | +4.3% | 32,600 | +5.5% | 0.18% | -6.3% |
| Q4 2016 | $3,176,000 | +8.6% | 30,890 | +15.6% | 0.19% | +21.0% |
| Q3 2016 | $2,925,000 | -19.6% | 26,711 | -17.2% | 0.16% | -21.9% |
| Q2 2016 | $3,638,000 | +52.3% | 32,257 | +27.7% | 0.20% | +32.2% |
| Q1 2016 | $2,388,000 | -33.4% | 25,265 | -36.6% | 0.15% | -13.6% |
| Q4 2015 | $3,586,000 | +36.4% | 39,841 | +40.1% | 0.18% | +36.4% |
| Q3 2015 | $2,629,000 | -45.6% | 28,432 | -42.1% | 0.13% | -30.6% |
| Q2 2015 | $4,833,000 | +2.6% | 49,077 | +4.5% | 0.19% | -0.5% |
| Q1 2015 | $4,710,000 | +73.6% | 46,963 | +59.9% | 0.19% | -1.1% |
| Q4 2014 | $2,713,000 | – | 29,363 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |